JP2020509050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509050A5 JP2020509050A5 JP2019547641A JP2019547641A JP2020509050A5 JP 2020509050 A5 JP2020509050 A5 JP 2020509050A5 JP 2019547641 A JP2019547641 A JP 2019547641A JP 2019547641 A JP2019547641 A JP 2019547641A JP 2020509050 A5 JP2020509050 A5 JP 2020509050A5
- Authority
- JP
- Japan
- Prior art keywords
- lineage
- epitope
- cell surface
- hematopoietic
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023192752A JP2024019176A (ja) | 2017-02-28 | 2023-11-13 | 系統特異的タンパク質の阻害のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464975P | 2017-02-28 | 2017-02-28 | |
| US62/464,975 | 2017-02-28 | ||
| PCT/US2018/020327 WO2018160768A1 (en) | 2017-02-28 | 2018-02-28 | Compositions and methods for inhibition lineage specific proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192752A Division JP2024019176A (ja) | 2017-02-28 | 2023-11-13 | 系統特異的タンパク質の阻害のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509050A JP2020509050A (ja) | 2020-03-26 |
| JP2020509050A5 true JP2020509050A5 (enExample) | 2021-04-15 |
| JP7386082B2 JP7386082B2 (ja) | 2023-11-24 |
Family
ID=63370206
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547641A Active JP7386082B2 (ja) | 2017-02-28 | 2018-02-28 | 系統特異的タンパク質の阻害のための組成物および方法 |
| JP2023192752A Pending JP2024019176A (ja) | 2017-02-28 | 2023-11-13 | 系統特異的タンパク質の阻害のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192752A Pending JP2024019176A (ja) | 2017-02-28 | 2023-11-13 | 系統特異的タンパク質の阻害のための組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11975029B2 (enExample) |
| EP (1) | EP3589291A4 (enExample) |
| JP (2) | JP7386082B2 (enExample) |
| KR (1) | KR102709603B1 (enExample) |
| CN (1) | CN110662554A (enExample) |
| AU (2) | AU2018229351B2 (enExample) |
| BR (1) | BR112019017751A2 (enExample) |
| CA (1) | CA3054808A1 (enExample) |
| IL (1) | IL268895B2 (enExample) |
| MX (1) | MX2019010196A (enExample) |
| RU (1) | RU2019130504A (enExample) |
| SG (1) | SG11201907870VA (enExample) |
| WO (1) | WO2018160768A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018004546A (es) | 2015-10-16 | 2019-04-15 | Univ Columbia | Composiciones y métodos para la inhibicion de antígenos específicos de linaje. |
| BR112019017751A2 (pt) | 2017-02-28 | 2020-04-07 | Vor Biopharma, Inc. | composições e métodos de inibição de proteínas de linhagem específica |
| US11718659B2 (en) * | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| KR20250134703A (ko) | 2018-05-11 | 2025-09-11 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 아미노산을 치환하는 방법 |
| US11389485B2 (en) | 2018-08-28 | 2022-07-19 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
| US12454694B2 (en) | 2018-09-07 | 2025-10-28 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| US12529041B2 (en) | 2018-09-07 | 2026-01-20 | Beam Therapeutics Inc. | Compositions and methods for delivering a nucleobase editing system |
| WO2020168122A1 (en) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| EP3924478A4 (en) * | 2019-02-13 | 2023-01-25 | Beam Therapeutics, Inc. | Compositions and methods for treating glycogen storage disease type 1a |
| US20220202900A1 (en) * | 2019-02-22 | 2022-06-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for crispr/cas9 knock-out of cd33 in human hematopoietic stem / progenitor cells for allogenic transplantation in patients with relapsed - refractory acute myeloid leukemia |
| KR20220035877A (ko) | 2019-05-23 | 2022-03-22 | 보르 바이오파마 인크. | Cd33 변형을 위한 조성물 및 방법 |
| KR20220047381A (ko) | 2019-08-28 | 2022-04-15 | 보르 바이오파마 인크. | Cd123 변형을 위한 조성물 및 방법 |
| KR20220047380A (ko) | 2019-08-28 | 2022-04-15 | 보르 바이오파마 인크. | Cll1 변형을 위한 조성물 및 방법 |
| US11723926B2 (en) | 2019-09-27 | 2023-08-15 | Starkage Therapeutics | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
| WO2021058795A2 (en) * | 2019-09-27 | 2021-04-01 | Stark Labs | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
| US20220380776A1 (en) * | 2019-10-22 | 2022-12-01 | Fred Hutchinson Cancer Center | Base editor-mediated cd33 reduction to selectively protect therapeutic cells |
| WO2021202770A2 (en) * | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Human anti-cd33 antibodies and uses thereof |
| CA3172691A1 (en) * | 2020-03-31 | 2021-10-07 | Cameron J. Turtle | Chimeric antigen receptors targeting cd33 |
| JP2023540277A (ja) | 2020-08-28 | 2023-09-22 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ１２３改変のための組成物および方法 |
| EP4204565A1 (en) | 2020-08-28 | 2023-07-05 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| US20240041932A1 (en) | 2020-09-14 | 2024-02-08 | Vor Biopharma Inc. | Compositions and methods for cd5 modification |
| JP2023541457A (ja) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ３８修飾のための化合物および方法 |
| WO2022061115A1 (en) | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| WO2022067089A1 (en) | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2022067240A1 (en) | 2020-09-28 | 2022-03-31 | Vor Biopharma, Inc. | Compositions and methods for cd6 modification |
| US20230364146A1 (en) | 2020-09-30 | 2023-11-16 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
| CA3199623A1 (en) * | 2020-10-27 | 2022-05-05 | Vor Biopharma Inc. | Compositions and methods for treating hematopoietic malignancy |
| US20240344058A1 (en) | 2020-10-30 | 2024-10-17 | Vor Biopharma Inc. | Compositions and methods for bcma modification |
| WO2022104090A1 (en) * | 2020-11-13 | 2022-05-19 | Vor Biopharma Inc. | Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors |
| US20240366675A1 (en) | 2020-12-31 | 2024-11-07 | Vor Biopharma Inc. | Compositions and methods for cd34 gene modification |
| WO2022228471A1 (zh) * | 2021-04-27 | 2022-11-03 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| EP4380693A1 (en) | 2021-08-06 | 2024-06-12 | Universität Basel | Discernible cell surface protein variants for use in cell therapy |
| JP2024543369A (ja) | 2021-11-09 | 2024-11-21 | ブイオーアール バイオファーマ インコーポレーテッド | Ｅｍｒ２修飾のための化合物及び方法 |
| US20250057951A1 (en) | 2021-12-16 | 2025-02-20 | Universität Basel | Discernible cell surface protein variants of cd117 for use in cell therapy |
| AU2022422572A1 (en) | 2021-12-23 | 2024-06-06 | Cimeio Therapeutics Ag | Discernible cell surface protein variants of cd45 for use in cell therapy |
| US20260009051A1 (en) | 2022-07-13 | 2026-01-08 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| CN116850210B (zh) * | 2023-01-17 | 2024-05-31 | 武汉大学 | 用于治疗急性髓系白血病的成分和方法 |
| EP4688850A1 (en) | 2023-04-03 | 2026-02-11 | Universität Basel | Discernible cell surface protein variants of cd33 for use in cell therapy |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| PH12012500714A1 (en) * | 2009-10-19 | 2012-10-29 | Tristem Trading Cyprus Ltd | Treatment using reprogrammed mature adult cells |
| CA2993567C (en) | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| PL4289948T3 (pl) | 2012-05-25 | 2025-06-02 | The Regents Of The University Of California | Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
| EP2833591A1 (en) | 2013-07-31 | 2015-02-04 | Siemens Aktiengesellschaft | Subsea data communication interface unit |
| EP4420663A3 (en) | 2013-12-20 | 2024-10-30 | Novartis AG | Regulatable chimeric antigen receptor |
| US10836998B2 (en) | 2014-02-14 | 2020-11-17 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| CA2943008C (en) | 2014-03-19 | 2021-03-30 | Cellectis | Cd123 specific chimeric antigen receptors for cancer immunotherapy |
| AU2015239069B2 (en) | 2014-04-03 | 2020-02-20 | Cellectis | CD33 specific Chimeric Antigen Receptors for cancer immunotherapy |
| EP3129485B2 (en) | 2014-04-09 | 2022-12-21 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
| CA2945393C (en) | 2014-04-24 | 2021-03-23 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| WO2015195547A1 (en) | 2014-06-16 | 2015-12-23 | University Of Washington | Methods for controlling stem cell potential and for gene editing in stem cells |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| JP6736540B2 (ja) | 2014-07-21 | 2020-08-05 | ノバルティス アーゲー | Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置 |
| SG10201913765YA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| CN113699113A (zh) | 2014-09-16 | 2021-11-26 | 桑格摩治疗股份有限公司 | 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物 |
| KR101799975B1 (ko) | 2014-10-31 | 2017-11-21 | 에스케이씨하이테크앤마케팅(유) | 액정표시장치용 색순도 향상 및 휘도 보상 필름 및 이를 포함하는 액정표시장치 |
| EP3025719B1 (en) * | 2014-11-26 | 2018-09-26 | Miltenyi Biotec GmbH | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| US10900034B2 (en) | 2014-12-03 | 2021-01-26 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
| WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
| US20180002435A1 (en) | 2015-01-26 | 2018-01-04 | Cellectis | mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS |
| KR102888521B1 (ko) | 2015-04-06 | 2025-11-19 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna |
| IL303972A (en) * | 2015-04-08 | 2023-08-01 | Novartis Ag | CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell |
| WO2016170176A1 (en) | 2015-04-22 | 2016-10-27 | Curevac Ag | Rna containing composition for treatment of tumor diseases |
| GB201507119D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| US20180355318A1 (en) * | 2015-04-29 | 2018-12-13 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| MX2018004546A (es) | 2015-10-16 | 2019-04-15 | Univ Columbia | Composiciones y métodos para la inhibicion de antígenos específicos de linaje. |
| EP4434589A3 (en) | 2015-10-23 | 2025-05-14 | President and Fellows of Harvard College | Evolved cas9 proteins for gene editing |
| AU2016349280B2 (en) * | 2015-11-04 | 2023-10-05 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene editing in hematopoietic stem cells |
| CA3004743A1 (en) | 2015-11-24 | 2017-06-01 | Cellerant Therapeutics, Inc. | Humanized anti-cll-1 antibodies |
| JP7208010B2 (ja) * | 2016-03-29 | 2023-01-18 | ユニバーシティ オブ サザン カリフォルニア | 癌を標的とするキメラ抗原受容体 |
| WO2017186718A1 (en) | 2016-04-25 | 2017-11-02 | Universität Basel | Allele editing and applications thereof |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| JP7591342B2 (ja) | 2016-06-08 | 2024-11-28 | プレシゲン，インコーポレイテッド | Ｃｄ３３特異的キメラ抗原受容体 |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| WO2018007263A1 (en) | 2016-07-06 | 2018-01-11 | Cellectis | Sequential gene editing in primary immune cells |
| MA46570B1 (fr) | 2016-10-21 | 2021-10-29 | Ose Immunotherapeutics | Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t |
| LT3535392T (lt) | 2016-11-02 | 2024-04-25 | Universität Basel | Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje |
| KR102618864B1 (ko) | 2016-12-30 | 2024-01-02 | 에디타스 메디신, 인코포레이티드 | 합성 가이드 분자, 그와 관련된 조성물 및 방법 |
| BR112019017751A2 (pt) | 2017-02-28 | 2020-04-07 | Vor Biopharma, Inc. | composições e métodos de inibição de proteínas de linhagem específica |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| BR112019021182A2 (pt) | 2017-04-24 | 2020-06-02 | Memorial Sloan Kettering Cancer Center | Agentes de anticorpo anti-cd33 |
| US11718659B2 (en) | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| WO2019152591A1 (en) | 2018-01-31 | 2019-08-08 | Hydroacoustics Inc. | Fluid sensor and pumpjack control system |
| EP3749764A1 (en) | 2018-02-08 | 2020-12-16 | Zymergen, Inc. | Genome editing using crispr in corynebacterium |
| TWI669677B (zh) | 2018-03-07 | 2019-08-21 | 光陽工業股份有限公司 | 充電座管理方法、用於充電座管理方法的伺服器及充電座 |
| US11389485B2 (en) | 2018-08-28 | 2022-07-19 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| CN113227141A (zh) | 2018-11-07 | 2021-08-06 | 克里斯珀医疗股份公司 | 抗cd33免疫细胞癌症疗法 |
| AU2020208616A1 (en) | 2019-01-16 | 2021-08-12 | Beam Therapeutics Inc. | Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance |
| CA3126677A1 (en) | 2019-01-16 | 2020-07-23 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| WO2020168122A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| KR20220035877A (ko) | 2019-05-23 | 2022-03-22 | 보르 바이오파마 인크. | Cd33 변형을 위한 조성물 및 방법 |
| EA202191979A1 (ru) | 2019-05-24 | 2021-11-01 | Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк | Композиции и способы ингибирования линиеспецифических антигенов |
| KR20220047380A (ko) | 2019-08-28 | 2022-04-15 | 보르 바이오파마 인크. | Cll1 변형을 위한 조성물 및 방법 |
| KR20220047381A (ko) | 2019-08-28 | 2022-04-15 | 보르 바이오파마 인크. | Cd123 변형을 위한 조성물 및 방법 |
-
2018
- 2018-02-28 BR BR112019017751-5A patent/BR112019017751A2/pt not_active Application Discontinuation
- 2018-02-28 WO PCT/US2018/020327 patent/WO2018160768A1/en not_active Ceased
- 2018-02-28 MX MX2019010196A patent/MX2019010196A/es unknown
- 2018-02-28 EP EP18760400.4A patent/EP3589291A4/en active Pending
- 2018-02-28 SG SG11201907870VA patent/SG11201907870VA/en unknown
- 2018-02-28 JP JP2019547641A patent/JP7386082B2/ja active Active
- 2018-02-28 IL IL268895A patent/IL268895B2/en unknown
- 2018-02-28 CA CA3054808A patent/CA3054808A1/en active Pending
- 2018-02-28 KR KR1020197028404A patent/KR102709603B1/ko active Active
- 2018-02-28 US US16/489,407 patent/US11975029B2/en active Active
- 2018-02-28 RU RU2019130504A patent/RU2019130504A/ru unknown
- 2018-02-28 AU AU2018229351A patent/AU2018229351B2/en active Active
- 2018-02-28 CN CN201880026602.0A patent/CN110662554A/zh active Pending
-
2023
- 2023-11-13 JP JP2023192752A patent/JP2024019176A/ja active Pending
-
2024
- 2024-03-28 US US18/620,496 patent/US20240350550A1/en active Pending
- 2024-04-03 AU AU2024202117A patent/AU2024202117A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020509050A5 (enExample) | ||
| US20250034217A1 (en) | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof | |
| Ben-Shmuel et al. | Unleashing natural killer cells in the tumor microenvironment–the next generation of immunotherapy? | |
| RU2019130504A (ru) | Композиции и способы ингибирования линиеспецифических белков | |
| KR102483822B1 (ko) | 태그된 키메라 이펙터 분자 및 그의 리셉터 | |
| TWI775768B (zh) | 新穎t細胞受器及使用其之免疫治療 | |
| RU2756247C2 (ru) | Генетически модифицированные гамма дельта т-клетки | |
| KR102095700B1 (ko) | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 | |
| Wang et al. | T-cell-based immunotherapy for osteosarcoma: challenges and opportunities | |
| JP2019536480A (ja) | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 | |
| US20220251572A1 (en) | Immune cells defective for suv39h1 | |
| US20190085081A1 (en) | Chimeric antigen receptor | |
| CN110494160A (zh) | T细胞受体及其针对prame阳性癌症的免疫治疗 | |
| KR20190036551A (ko) | Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료 | |
| JP2016520074A5 (enExample) | ||
| US20250152717A1 (en) | Binding proteins and engineered cells specific for neoantigens and uses thereof | |
| US20230348854A1 (en) | Chimeric antigen receptors (cars) targeting natural killer cells | |
| JP2022514320A (ja) | Ｃｄ２２特異的なｔ細胞受容体およびｂ細胞悪性腫瘍の処置のための養子ｔ細胞療法 | |
| KR20200085776A (ko) | 신규한 감마 델타 t-세포 수용체 및 이의 리간드 | |
| BR112021010132A2 (pt) | Células car-t alogênicas derivadas da placenta e usos da mesmas | |
| WO2019140278A1 (en) | Immunotherapy targeting core binding factor antigens | |
| CA3250186A1 (en) | Specific binding proteins for RAS neo-antigens and their uses | |
| CN119912567B (zh) | 一种表达靶向B7-H3的嵌合抗原受体的Vγ9Vδ2 T细胞及其应用 | |
| KR20260013488A (ko) | 면역 이펙터 세포 및 이의 용도 | |
| WO2025245169A1 (en) | Immunotherapy cells equipped with a collagen-targeting payload |